Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
Igawa S, Ono T, Kasajima M, Kusuhara S, Otani S, Fukui T, Yokoba M, Kubota M, Katagiri M, Mitsufuji H, Sasaki J, Naoki K.
Igawa S, et al. Among authors: naoki k.
Invest New Drugs. 2020 Dec;38(6):1906-1914. doi: 10.1007/s10637-020-00948-9. Epub 2020 May 15.
Invest New Drugs. 2020.
PMID: 32415486